Aims
The Primary Aims are to characterize and compare regimens HARVONI®, Viekira Pak™ and Zepatier™ on the following patient-centered outcomes:
- treatment effectiveness (i.e., sustained viral response 12 weeks post-treatment, “SVR12”) and
- drug side (both patient reported and medical record abstracted)
- efficacy of ZEPATIER™ with RBV for 16 weeks when used in G1A patients with baseline resistance associated polymorphisms (RAPs)
The Secondary Aims are to characterize and compare regimens (HARVONI®, Viekira Pak™, and Zepatier™) on the following outcomes:
- treatment adherence and persistence;
- amelioration of systemic HCV‐associated symptoms post-treatment;
- post-treatment progression and regression of liver disease
- persistence of viral cure for 3 years post-treatment; and
- functional status on treatment and after
- impact of baseline NS5A RAPs on treatment outcomes